Comparative Pharmacology
Head-to-head clinical analysis: DEXACORT versus TRIATEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACORT versus TRIATEX.
DEXACORT vs TRIATEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
TRIATEX (methotrexate) inhibits dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby interfering with DNA synthesis, repair, and cellular replication. It also has immunomodulatory and anti-inflammatory effects through adenosine-mediated pathways.
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
Triatex (trianterene/hydrochlorothiazide) 37.5 mg/25 mg or 75 mg/50 mg orally once daily; may increase to maximum of 2 capsules daily.
None Documented
None Documented
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
Terminal elimination half-life is 8-12 hours (mean 10 hours) in adults with normal renal function; prolonged to 20-40 hours in moderate-severe renal impairment (CrCl <30 mL/min).
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Primarily renal excretion (80-90% as unchanged drug via glomerular filtration and active tubular secretion) with 5-10% fecal elimination.
Category C
Category C
Corticosteroid
Corticosteroid